<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118360</url>
  </required_header>
  <id_info>
    <org_study_id>ASC41-201</org_study_id>
    <nct_id>NCT05118360</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH</brief_title>
  <official_title>A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gannex Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gannex Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy&#xD;
      confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults&#xD;
      with NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">January 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized in 2:1 ratio to receive either oral ASC41 2 mg or oral matching placebo. Randomized in 2:1 ratio to receive either oral ASC41 4 mg or oral matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of ASC41 subjects compared to placebo with histological reduction in NAS ≥2 points that results from reduction of inflammation or ballooning and no worsening fibrosis assessed by histopathological reading of liver biopsy at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of ASC41 evaluated by incidence of treatment emergent adverse events (TEAEs) in ASC41 treated subjects compared to placebo</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic fat fraction based on MRI-PDFF measurements in ASC41 treated subjects compared to placebo.</measure>
    <time_frame>Baseline to Week 12 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of NASH on overall histopathological reading of liver biopsy specimen taken at Week 52 compared to baseline in ASC41 treated subjects compared to placebo treated subjects</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Part 1-ASC41 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 2mg for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-ASC41 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASC41 4 mg for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC41 2 mg</intervention_name>
    <description>2mg of ASC41 orally once daily for 52 weeks</description>
    <arm_group_label>Part 1-ASC41 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASC41 4 mg</intervention_name>
    <description>4mg of ASC41 orally once daily for 52 weeks</description>
    <arm_group_label>Part 2-ASC41 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo orally once daily for 52 weeks.</description>
    <arm_group_label>Part1-placebo</arm_group_label>
    <arm_group_label>Part2-placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Presence of ≥ 8% liver fat content on screening MRI-PDFF.&#xD;
&#xD;
          -  Histologic evidence of NASH upon central read of a liver biopsy obtained no more than&#xD;
             6 months before Day 1 defined by NASH activity score (NAS) greater than or equal to 4&#xD;
             with at least 1 point each in inflammation and ballooning.&#xD;
&#xD;
          -  Diabetes Mellitus well controlled based on laboratory test HbA1c ≤ 9.5%.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of advanced liver disease such as cirrhosis (stage 4 fibrosis) or&#xD;
             decompensated liver disease (e.g. ascites, esophageal varices) or liver cancer.&#xD;
&#xD;
          -  Evidence of other causes of chronic liver disease.&#xD;
&#xD;
          -  Weight change ≥ 5% after qualifying liver biopsy or MRI-PDFF performed.&#xD;
&#xD;
          -  Any contraindications to a MRI scan.&#xD;
&#xD;
          -  Treatment with vitamin E (unless stable dose of &lt; 400 IU/d), thiazolidinediones (TZD),&#xD;
             or glucagon-like peptide-1 receptor agonists (GLP-1 RA), unless subject is on a stable&#xD;
             dose for 6 months prior to qualifying liver biopsy.&#xD;
&#xD;
          -  Known history of alcohol or other substance abuse within the last year or at any time&#xD;
             during the study.&#xD;
&#xD;
          -  Use of any investigational drug within 6 months of MRI-PDFF and/or liver biopsy.&#xD;
&#xD;
          -  Known positivity for antibody to Human Immunodeficiency Virus (HIV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gannex Study Doctor</last_name>
    <phone>+86 571 85389730</phone>
    <email>clinicaltrials@ascletis.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Thyroid hormone receptor agonist</keyword>
  <keyword>NASH</keyword>
  <keyword>ASC41</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

